Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of the deal, the U.S.
Merck sets sights on brain cancer with $30M Modifi acquisition
Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma.
Merck acquires Modifi Biosciences in $1.3bn cancer therapy deal
The acquisition strengthens Merck's oncology portfolio as the company looks to off the expiration of the patent for pembrolizumab.
Merck acquires Modifi Biosciences for $30M upfront
Modifi Biosciences announced that the company has been acquired by Merck (MRK). Under the terms of the agreement Merck, through a subsidiary,
Modifi Biosciences Acquired by Merck
Modifi Biosciences, Inc. ("Modifi Biosciences"), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company has been acquired by Merck, known as MSD outside of the United States and Canada.
Merck buys Modifi for $30M plus up to $1.3B in potential payments
Merck (NYSE:MRK) has acquired Modifi Biosciences, a developer of DNA modification-enabled cancer drugs, for $30M upfront and up to $1.3B in potential milestone payments. Modifi, a spinout of Yale University,
2h
on MSN
Merck Keytruda cleared in EU for two new indications in gynecologic cancers
Merck’s (NYSE:MRK) blockbuster cancer therapy Keytruda (pembrolizumab) has been cleared by the European Commission to treat ...
2h
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers
Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app ...
FiercePharma
15h
In boon for Pfizer and Merck, CDC panel backs expanded use of pneumococcal vaccines
With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...
BioWorld
1d
Modifi acquired by Merck in $1.3B deal
Spun out of Yale University in 2021, it published data on DNA in Science in July 2022, and now it’s being acquired by
Merck
...
2d
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?
We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates ...
6d
Merck's RSV antibody for infants effective in reducing some types of infections in study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...
21h
Merck & Company (MRK) Receives a Buy from Jefferies
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...
The Journal
1d
Merck Animal Health introduces SENSEHUB Dairy Youngstock
Merck
Animal Health, a division of
Merck
& Co., Inc., Rahway, New Jersey, has introduced SENSEHUB Dairy Youngstock, the ...
Business Wire
1h
Merck Foundation Awarded the “NGO of the Year 2024” for Leading Community Empowerment in Africa by Voters’ Choice
Merck Foundation Awarded the “NGO of the Year 2024” for Leading Community Empowerment in Africa by Voters’ Choice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Modifi Biosciences
New York Stock Exchange
RSV
MRK
Pfizer
Feedback